Kutinová L, Benda R, Kalos Z, Dbalý V, Votruba T, Kvícalová E, Petrovská P, Doutlík S, Kamínková J, Domorázková E
Department of Experimental Virology, Institute of Sera and Vaccines, Prague.
Vaccine. 1988 Jun;6(3):223-8. doi: 10.1016/0264-410x(88)90215-0.
The safety and efficacy of a subunit herpes simplex virus (HSV) type 1 vaccine were tested in a small-scale double-blind trial carried out in a group of 42 volunteers suffering from frequent recurrences of herpetic lesions. The patients were paired according to sex, age, type of virus isolated, previous history of the disease and some non-specific immunological markers. One member of each pair received repeated doses of HSV vaccine, the other a placebo. Clinical reactions were mild. Antibody responses following the vaccination were generally low and were almost entirely limited to subjects suffering from HSV-2 lesions. A majority of the patients exhibited improvement of their condition during the postvaccination period. These improvements were, however, nearly equally distributed between the vaccine and placebo groups.
一种1型单纯疱疹病毒（HSV）亚单位疫苗的安全性和有效性在一项小规模双盲试验中进行了测试，该试验在一组42名频繁出现疱疹性损伤复发的志愿者中开展。患者根据性别、年龄、分离出的病毒类型、疾病既往史和一些非特异性免疫标志物进行配对。每对中的一名成员接受重复剂量的HSV疫苗，另一名接受安慰剂。临床反应轻微。接种疫苗后的抗体反应总体较低，几乎完全局限于患有HSV-2损伤的受试者。大多数患者在接种疫苗后的时期内病情有所改善。然而，这些改善在疫苗组和安慰剂组之间几乎平均分布。
